CUR Share Price

Open 0.01 Change Price %
High 0.02 1 Day 0.01 100.00
Low 0.01 1 Week 0.00 0.00
Close 0.02 1 Month 0.00 0.00
Volume 219000 1 Year -0.08 -80.00
52 Week High 0.17
52 Week Low 0.01
CUR Important Levels
Resistance 2 0.03
Resistance 1 0.03
Pivot 0.02
Support 1 0.01
Support 2 0.01
TSE Canada Most Active Stocks
BIN 41.40 -1.62%
BIN 41.40 -1.62%
LSG 2.08 8.33%
LSG 2.08 8.33%
LSG 2.08 8.33%
TBE 0.03 0.00%
BTO 3.38 1.81%
BTO 3.38 1.81%
SC 60.83 -0.44%
PRE 0.64 0.00%
More..
TSE Canada Top Gainers Stocks
CUR 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
TVI 0.02 100.00%
DA-A 0.23 35.29%
ANX 0.06 20.00%
ANX 0.06 20.00%
CUM 0.90 13.92%
CUM 0.90 13.92%
CXA-B 1.10 11.11%
More..
TSE Canada Top Losers Stocks
GBV 0.46 -24.59%
PWC 0.10 -16.67%
PWC 0.10 -16.67%
TOS 2.25 -11.42%
TOS 2.25 -11.42%
BX 0.85 -10.53%
BX 0.85 -10.53%
CET 0.48 -9.43%
CET 0.48 -9.43%
DNT 0.10 -9.09%
More..

Diagnocure Inc (TSE: CUR)

CUR Technical Analysis 5
As on 6th Jun 2016 CUR Share Price closed @ 0.02 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.10 & Strong Sell for SHORT-TERM with Stoploss of 0.03 we also expect STOCK to react on Following IMPORTANT LEVELS.
CUR Target for December
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
CUR Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.diagnocure.com
CUR Address
CUR
4535 Wilfrid-Hamel Boulevard
Suite 250
Quebec, QC G1P 2J7
Canada
Phone: 418-527-6100
Fax: 418-527-0240
CUR Latest News
Imaging Biomarkers Market - Evolving Technology, Trends and Industry Analysis ...   Medgadget (blog)   - 16th Nov 16
DiagnoCure announces results of its Annual and Special Meeting of shareholders   PR Newswire (press release)   - 20th May 16
Diagnocure announces its decision to proceed with the voluntary Liquidation ...   PR Newswire (press release)   - 15th Apr 16
Leads for New M&A Rose in February, but the Tally for Closed Deals Kept Falling   Mergers & Acquisitions - The Middle Market   - 05th Mar 16
DiagnoCure announces closing of the PCA3 Asset Sale transaction and special ...   PR Newswire (press release)   - 18th Feb 16
DiagnoCure announces the execution of an Asset Purchase Agreement   PR Newswire (press release)   - 24th Dec 15
DiagnoCure's new prostate cancer multimarker urine test featured at a recent ...   PR Newswire (press release)   - 21st May 15
DiagnoCure appoints Richard Bordeleau as Senior Advisor to the board   PR Newswire (press release)   - 20th Aug 13
FDA approves PROGENSA┬« PCA3 assay   PR Newswire (press release)   - 15th Feb 12
The Future of Molecular Diagnostics: Innovative Technologies Driving Market ...   PR Newswire (press release)   - 08th Nov 10
Interactive Technical Analysis Chart Diagnocure Inc ( CUR TSE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Diagnocure Inc
CUR Business Profile
DiagnoCure Inc., a life sciences company, develops and commercializes cancer diagnostic tests for the detection and management of cancer. The company primarily focuses on molecular diagnostic tests. It offers PCA3 test for the diagnosis of prostate cancer; and GCC marker, Previstage GCC staging test, GCC monitoring blood test, Shc proteins, and scientific publications for use in colorectal cancer management. The company was founded in 1994 and is headquartered in Quebec, Canada.